Short answer
Labcorp (LH) filed an 8-K current report with the SEC on September 10, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.2). 2026 Investor Day outlined Labcorp’s growth strategy, innovation roadmap, and long-term financial outlook through 2029.
Labcorp 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- 2026 Investor Day outlined Labcorp’s growth strategy, innovation roadmap, and long-term financial outlook through 2029
- Full-year 2026 guidance reaffirmed, reducing near-term guidance uncertainty
- Press release and investor presentation furnished as Exhibits 99.1 and 99.2, containing substantive strategy and forecast details
- Investors should review the exhibits for 2029 targets, growth drivers, and execution priorities
Item EX-99.1 · Exhibit EX-99.2
- Reaffirms 2026 revenue guidance of $14,710–$14,827 million and adjusted EPS of $18.10–$18.55
- 2026 free cash flow guidance remains $1,240–$1,360 million, supporting capital returns and investment
- Long-term outlook through 2029 targets 5%–8% annual revenue growth and 8.5%–11.5% adjusted EPS growth
- Adjusted operating margin expected to expand 75–150 basis points by 2029
- Growth strategy centers on specialty testing, personalized health, biopharma partnerships, AI and robotics
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Labcorp 8-K filings
Get the next LH 8-K as it lands
Follow LH for push alerts, or ask the research agent what this filing means.